A 2020 cluster randomized trial found no difference in in-hospital mortality among nearly 27,000 mechanically patients assigned to an intensive care unit (ICU)-level strategy of stress ulcer prophylaxis with proton pump inhibitors (PPIs) vs histamine-2 receptor blockers (H2RBs). Paul J. Young, PhD, of Wellington Hospital in New Zealand, presented findings from the PEPTIC Trial at the Critical Care Reviews 2020 meeting (CCR20), on January 17 in Belfast, Northern Ireland. An oral editorial and Q&A session follows. Click the related article link for full trial details. Video used with permission.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
You currently have no searches saved.
You currently have no courses saved.